Abbott, BD and F. Hoffmann La Roche Ltd. are dominating the Latin America Point of Care Infectious Disease Market in 2019

Latin America Point of Care Infectious Disease Market is expected to grow with the CAGR of 8.3% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report@ https://www.databridgemarketresearch.com/reports/latin-america-point-of-care-infectious-disease-market

Latin America point of care infectious disease market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in Latin America point of care infectious disease market are introducing strong range of product portfolio. This helped companies to maximize the sales with enhanced product portfolio. For instance, in June 2019, BD announced that the company has received certification for CE-IVDD of the BD COR System in Europe. This high throughput solution for infectious disease diagnostics sets a new standard in automation for molecular testing in core laboratories and other large centralized laboratories.

Abbottis the dominating player in Latin America point of care infectious disease market.The other key players existing in the market includesBD, BioMérieux SA, F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Chembio Diagnostic Systems, Inc., Cardinal health, Koninklijke Philips N.V. and Thermo Fisher Scientific, Inc.

Latin America Point of Care Infectious Disease Market

Abbott

AbbottheadquarteredinIllinois, U.S.which was foundedin 1888.The company is engaged in manufacturing and commercializing products and services for healthcare professionalsand their business segments established pharmaceuticals, nutritionals, diagnostic, cardiovascular and neuromodulationout of which market focused segment is diagnostic.

  • In March, 2020, Abbott launched a molecular point-of-care test that is capable of detecting novel coronavirus in as little as five minutes.  The test runs on the company’s point-of-care ID NOW platform. This is expected to be an achievement for the company in times of need.

The company has wide Latin America presence across the globe such as North America, Latin America, Europe, Middle East and Africa, Asia-Pacific. In addition to it, the company also generates its revenue from the various subsidiary companiessuch asAbbott Administration Inc.(Delaware), Abbott Cardiovascular Systems Inc. (California), Abbott Home Infusion Services of New York, Inc.(New York), Abbott Laboratories (Puerto Rico) Incorporated, EAS Australia Pty Ltd (Australia), Abbott (Cambodia) LLC, Abbott Laboratories A/S (Denmark) among others.

BD

BDis headquartered in New Jersey, U.S.and itwas foundedinyear 1897.The company is engaged in the development, manufacture and sales of medical supplies, devices, laboratory equipment and diagnostic products.The company offers wide range of product categoriessuch as biosciences, cervical cancer screening, diabetes care, drug delivery systems, genomics, hazardous drug safety, infection prevention, infusinon therapy, interventional speciality, interventional  specialities, medication and supply management, microbiology solution, molecular diagnostics, sharps disposal solutions, software solutions, specimen collection, surgical instruments, syringes and needlesunderwhich consumer infection preventionis market focused category.

  • In June 2019, the company announced the CE-IVDD certification of the BD COR System. It is an automated solution for infectious disease diagnostics for molecular testing in core laboratories and other large centralized laboratories. This expands the company’s portfolio in molecular diagnostics.

The company has presence in Eastern Europe, Middle East, Africa, Latin America, AsiaPacific. with its various subsidiaries such as CareFusion (U.S.), C. R. Bard (U.S), Accuri Cytometers Inc. (U.S.), TVA Medical, Inc.  (U.S.), Becton Dickinson AcuteCare Inc.(West Africa), TriPath Imaging, Inc. (U.S.) among others.

F. Hoffmann-La Roche Ltd

F. Hoffmann-La Roche Ltd is headquartered in Basel, Switzerland which was founded in 1665. The company delivers medical solutions in order to change patient’s life. The company has business segments which pharmaceuticals and diagnosticsamong which diagnostics is market focused segment.

  • In January 2020, F. Hoffmann-La Roche Ltd announced that the company entered into a 15-year, non-exclusive partnership with Illumina to broaden the adoption of distributable next-generation sequencing (NGS) based testing in oncology. This agreement brings together complementary capabilities of each company to broaden global adoption of NGS in cancer care.

The company has wide Latin America presence in Europe, North America, Asia, Africa, Australia and Oceania. In addition to it, the company also generates its revenue from the various subsidiary companies such as Genentech, Inc (U.S.), RocheDiagnostics Limited (U.K.), Chugai Pharmaceutical Co (Japan), Flatiron Health, Inc (U.S.), Ventana Medical Systems (U.S.), Kapa Biosystems, Inc (U.S.)